Innowacyjne podejście do diagnostyki i leczenia nowotworu piersi

Giunti G, Giunta DH, Guisado-Fernandez E, Bender JL, Fernandez-Luque L. A biopsy of Breast Cancer mobile applications: state of the practice review. International Journal of Medical Informatics: Int J Med Inform. 2018;110:1-9.doi:10.1016/j.ijmedinf.2017.10.022

World Health Organisation. Breast Cancer. https://www.who.int/news-room/fact-sheets/detail/breast-cancer. Opublikowano: 26.03.2021. Dostęp: 16.01.2023.

Benson JR, Jatoi I, Keisch M, Esteva FJ, Makris A, Jordan VC. Early breast cancer. Lancet. 2009;373(9673):1463-1479.doi:10.1016/S0140-6736(09)60316-0

Rangayyan RM, Ayres FJ, J.E. Desautels L. A review of computer-aided diagnosis of breast cancer: Toward the detection of subtle signs, Journal of the Franklin Institute: J Franklin Inst. 2007;344:312-348.doi.org/10.1016/j.jfranklin.2006.09.003

Bartoszewska J, Brzuszkiewicz K, Bulanda R, Górski M, Hodorowicz- Zaniewska D, Michałowska- Kaczmarczyk A, Potocki P, Schwarz J, Streb J, Szpor J, Wadowska- Jaszczyńska K. Pierwsi do piersi, czyli jak wyprzedzić raka. Kraków, Polska: Uniwersyteckie Centrum Leczenia Chorób Piersi. Szpital Uniwersytecki w Krakowie. 2021;(1-14):7-126.

Kamińska M, Ciszewski T, Łopacka-Szatan K, Miotła P, Starosławska E. Breast cancer risk factors. Przegląd Menopauzalny: Prz Menopauzalny. 2015;14(3):196-202.doi: 10.5114/pm.2015.54346

Momenimovahed Z, Salehiniya. Epidemiological characteristics of and risk factors for breast cancer in the world. Breast Cancer (Dove Med Press). 2019;11:151–164.doi: 10.2147/BCTT.S176070

Sun YS, Zhao Z, Yang ZN, et al. Risk Factors and Preventions of Breast Cancer. International Journal of Biological Sciences: Int J Biol Sci. 2017;13(11):1387-1397.doi:10.7150/ijbs.21635

Mavaddat N, Antoniou AC, Easton DF, Garcia-Closas M. Genetic susceptibility to breast cancer. Molecular Oncology: Mol Oncol. 2010;4:174-191.doi:10.1016/j.molonc.2010.04.011

Jóźwik, M, Posmyk R, Semczuk, A, Gogiel-Shields, M, Kuś-Słowińska M, Garbowicz M, Klukowski M, Wojciechowicz J. Breast cancer in an 18-year-old female: A fatal case report and literature review. Cancer Biology & Therapy: Cancer Biol. Ther. 2018;19:543-548.doi.org/10.1080/15384047.2017.1416931

Shiyanbola OO, Arao RF, Miglioretti DL, Sprague BL, Hampton JM, Stout NK, Kerlikowske K, Braithwaite D, Buist DSM, Egan KM, Newcomb PA, Trentham-Dietz A. Emerging Trends in Family History of Breast Cancer and Associated Risk. Cancer Epidemiology, Biomarkers & Prevention: Cancer Epidemiol Biomarkers Prev. (2017);26(12):1753–1760.doi.org/10.1158/1055-9965.EPI-17-0531

Singh V, Saunders C, Wylie L, Bourke A. New diagnostic techniques for breast cancer detection. Future Oncology: Future Oncol. 2008;4(4):501-513.doi:10.2217/14796694.4.4.501

Więckowska B, Maciejczyk A. Innowacyjna onkologia. POTRZEBY. MOŻLIWOŚCI. SYSTEM. Warszawa, Polska: PZWL Wydawnictwo Lekarskie. 2020; (4-5)112- 113, 117.

James J. Contrast-enhanced spectral mammography (CESM)-guided breast biopsy as an alternative to MRI-guided biopsy. The British Journal of Radiology: Br J Radiol. 2022;95(1132):20211287. doi:10.1259/bjr.20211287

Santos Aragon LN, Soto-Trujillo D. Effectiveness of Tomosynthesis Versus Digital Mammography in the Diagnosis of Suspicious Lesions for Breast Cancer in an Asymptomatic Population. Cureus. 2021;13(3):13838.doi:10.7759/cureus.13838

Pujara AC, Kim E, Axelrod D, Melsaether AN. PET/MRI in Breast Cancer. Journal of Magnetic Resonance Imaging: J Magn Reson Imaging. 2019;49(2):328-342.doi:10.1002/jmri.26298

Flanagan FL, Dehdashti F, Siegel BA. PET in breast cancer. Seminars in Nuclear Medicine: Semin Nucl Med. 1998;28:290-302.doi:10.1016/s0001-2998(98)80034-2

Yoo HJ, Lee JS, Lee JM. Integrated whole body MR/PET: where are we?. Korean Journal of Radiology: Korean J Radiol. 2015;16(1):32-49.doi:10.3348/kjr.2015.16.1.32

Jabeen K, Khan MA, Alhaisoni M, et al. Breast Cancer Classification from Ultrasound Images Using Probability-Based Optimal Deep Learning Feature Fusion. Sensors (Basel). 2022;22(3):807.doi:10.3390/s22030807

Gordon PB. Ultrasound for breast cancer screening and staging. Radiologic Clinics of North America: Radiol Clin North Am. 2002;40(3):431-441.doi:10.1016/s0033-8389(01)00014-8

Boca Bene I, Dudea SM, Ciurea AI. Contrast-Enhanced Ultrasonography in the Diagnosis and Treatment Modulation of Breast Cancer. Journal of Personalized Medicine: J Pers Med. 2021;11(2):81.doi:10.3390/jpm11020081

Boca Bene I, Ciurea AI, Ciortea CA, Dudea SM. Pros and Cons for Automated Breast Ultrasound (ABUS): A Narrative Review. Journal of Personalized Medicine: J Pers Med. 2021;11(8):703.doi:10.3390/jpm11080703

Rella R, Belli P, Giuliani M, et al. Automated Breast Ultrasonography (ABUS) in the Screening and Diagnostic Setting: Indications and Practical Use. Academic Radiology: Acad Radiol. 2018;25(11):1457-1470.doi:10.1016/j.acra.2018.02.014

Eberl MM, Fox CH, Edge SB, Carter CA, Mahoney MC. BI-RADS classification for management of abnormal mammograms.The Journal of the American Board of Family Medicine: J Am Board Fam Med. 2006;19(2):161-164.doi:10.3122/jabfm.19.2.161

Webster LR, Bilous AM, Willis L, et al. Histopathologic indicators of breast cancer biology: insights from population mammographic screening. British Journal of Cancer: Br J Cancer. 2005;92(8):1366-1371.doi:10.1038/sj.bjc.6602501

Yari Y, Nguyen TV and Nguyen HT. Deep Learning Applied for Histological Diagnosis of Breast Cancer. Institute of Electrical and Electronics Engineer: IEEE. 2020;8:162432-162448.doi: 10.1109/ACCESS.2020.3021557

Ramljak V, Šarčević B, Velemir Vrdoljak D, Bobuš Kelčec I, Agai M, Trutin Ostović K. Fine Needle Aspiration Cytology in Diagnosing Rare Breast Carcinoma – Two Case Reports. Collegium antropologicum: Coll. Antropol. 2010;34(1):201-205.https://hrcak.srce.hr/51265. Dostęp: 16.01.2023.

Amedee RG, N. Dhurandhar NR. Fine-Needle Aspiration Biopsy. The Laryngoscope. 2001;111(9)1551-1557.doi:10.1097/00005537-200109000-00011

A. A. Renshaw, N. Pinnar. Comparison of Thyroid Fine-Needle Aspiration and Core Needle Biopsy. merican Journal of Clinical Pathology: Am J Clin Pathol. 2007;128(3):370-374.doi:10.1309/07TL3V58337TXHMC

Abe H, Schmidt RA, Sennett CA, Shimauchi A, Newstead GM. US-guided core needle biopsy of axillary lymph nodes in patients with breast cancer: why and how to do it. Radiographics. 2007;27 (supl 1):91-S99.doi:10.1148/rg.27si075502

Pan S, Liu W, Jin K, Liu Y, Zhou Y. Ultrasound-guided vacuum-assisted breast biopsy using Mammotome biopsy system for detection of breast cancer: results from two high volume hospitals. International Journal of Clinical and Experimental Medicine: Int J Clin Exp Med.2014;7(1):239-246.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3902263/. Dostęp: 16.01.2023.

Weigelt B, Geyer FC, Reis-Filho JS. Histological types of breast cancer: how special are they? Molecular Oncolgy: Mol Oncol. 2010;4(3):192-208.doi:10.1016/j.molonc.2010.04.004

Gomes do Nascimento R, Mormino Otoni K. Histological and molecular classification of breast cancer: what do we know? doi: 10.29289/25945394202020200024

Cristofanilli M, Gonzalez-Angulo A, Sneige N, et al. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes [korekta: Journal of Clinical Oncology: J Clin Oncol. 2013;31(23):2977. Buccholz, Thomas A [korekta: Buchholz, Thomas A]]. Journal of Clinical Oncology: J Clin Oncol. 2005;23(1):41-48.doi:10.1200/JCO.2005.03.111

Pal SK, Lau SK, Kruper L, et al. Papillary carcinoma of the breast: an overview. Breast Cancer Research and Treatment: Breast Cancer Res Treat. 2010;122(3):637-645.doi:10.1007/s10549-010-0961-5

Rakha EA, Reis-Filho JS, Baehner F, et al. Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Research: Breast Cancer Res. 2010;12(4):207.doi:10.1186/bcr2607

Tabar L. Rak Piersi; Warszawa: Medipage; 2010

Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16):1233-1241.doi:10.1056/NEJMoa022152

Jassem J, Krzakowski M, Bobek-Billewicz B, et al. Breast cancer. Oncol Clin Pract 2020; 21-26:16.doi:10.5603/OCP.2020.0038

Lyman GH, Temin S, Edge SB, et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2014;32(13):1365-1383. doi:10.1200/JCO.2013.54.1177

Biganzoli L, Cardoso F, Beishon M, et al. The requirements of a specialist breast centre. Breast. 2020;51:65-84. doi:10.1016/j.breast.2020.02.003

Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Darby S, McGale P, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378(9804):1707-1716. doi:10.1016/S0140-6736(11)61629-2

Smith BD, Bentzen SM, Correa CR, et al. Fractionation for whole breast irradiation: an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Int J Radiat Oncol Biol Phys. 2011;81(1):59-68. doi:10.1016/j.ijrobp.2010.04.042

Bartelink H, Maingon P, Poortmans P, et al. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial [published correction appears in Lancet Oncol. 2015 Jan;16(1):e6]. Lancet Oncol. 2015;16(1):47-56. doi:10.1016/S1470-2045(14)71156-8

Vicini FA, Cecchini RS, White JR, et al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet. 2019; 394(10215): 2155–2164, doi: 10.1016/S0140- 6736(19)32514-0

Whelan TJ, Julian JA, Berrang TS, et al. RAPID Trial Investigators. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet. 2019; 394(10215): 2165–2172, doi: 10.1016/S0140-6736(19)32515-2

Whelan TJ, Olivotto IA, Levine MN, et al. MA.20 Study Investigators. Regional Nodal Irradiation in Early-Stage Breast Cancer. N Engl J Med. 2015; 373(4): 307–316, doi: 10.1056/NEJMoa1415340

Journal of Oncology, NOWOTWORY 2012; 62, 6: 450–454.

Pogoda K, Jagiełło-Gruszfeld A, Niwińska A et al. Sacituzumab govitecan — a new therapy for patients with triple-negative breast cancer. Oncol Clin Pract. doi: 10.5603/OCP.2022.0003

Pogoda K, Niwińska A, Murawska M, Pieńkowski T. Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients. Med Oncol. 2013;30(1):388. doi:10.1007/s12032-012-0388-4

Ramesh M, Ahlawat P, Srinivas NR. Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives. Biomed Chromatogr. 2010;24(1):104-123. doi:10.1002/bmc.1345

Goldenberg DM, Cardillo TM, Govindan SV, Rossi EA, Sharkey RM. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) [published correction appears in Oncotarget. 2020 Mar 10;11(10):942]. Oncotarget. 2015;6(26):22496-22512. doi:10.18632/oncotarget.4318

Zhao W, Kuai X, Zhou X, et al. Trop2 is a potential biomarker for the promotion of EMT in human breast cancer. Oncol Rep. 2018;40(2):759-766. doi:10.3892/or.2018.6496

Ambrogi F, Fornili M, Boracchi P, et al. Trop-2 is a determinant of breast cancer survival. PLoS One. 2014; 9(5): e96993, doi: 10.1371/journal. pone.0096993

Bardia A, Mayer IA, Diamond JR, et al. Efficacy and Safety of Anti- -Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer. J Clin Oncol. 2017; 35(19): 2141–2148, doi: 10.1200/ JCO.2016.70.8297

Bardia A, Hurvitz SA, Tolaney SM, et al. ASCENT Clinical Trial Investigators. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2021; 384(16): 1529–1541, doi: 10.1056/ NEJMoa2028485

Bardia A, Mayer IA, Vahdat LT, et al. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2019; 380(8): 741–751, doi: 10.1056/NEJMoa1814213

Bardia A, Tolaney SM, Punie K, et al. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Ann Oncol. 2021; 32(9): 1148–1156, doi: 10.1016/j.annonc.2021.06.002

Struciński P, Ludwicki JK, Góralczyk K, Czaja K. Wybrane aspekty działania ksenoestrogenów z grupy persystentnych poprzez chloroorganiczne. Rocz. Państwowego Zakładu Hig. 2000; 51 :211–228.

Maciążek-Jurczyk M, Maliszewska M, Szkudlarek-Haśnik A. Chemoprewencja w raku piersi. Gospodarstwo rolne. Przegląd Nauk. 2010; 10 :34–40.

Milne RL, Antoniou AC. Modifiers of breast and ovarian cancer risks for BRCA1 and BRCA2 mutation carriers. Endocr Relat Cancer. 2016;23(10):T69-T84. doi:10.1530/ERC-16-0277

Li, X i in. Skuteczność operacji profilaktycznych u nosicieli mutacji BRCA1 lub BRCA2 : metaanaliza i przegląd systematyczny. Clin. Rak Res. 22 , 3971–3981 (2016), doi:10.1158/1078-0432.CCR-15-1465 https://doi.org/10.1158/1078-0432.CCR-15-1465

Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med. 1999;340(2):77-84. doi:10.1056/NEJM199901143400201

Carbine NE, Lostumbo L, Wallace J, Ko H. Risk-reducing mastectomy for the prevention of primary breast cancer. Cochrane Database Syst Rev. 2018;4(4):CD002748. Published 2018 Apr 5. doi:10.1002/14651858.CD002748.pub4

Jakub JW, Peled AW, Gray RJ, et al. Oncologic Safety of Prophylactic Nipple-Sparing Mastectomy in a Population With BRCA Mutations: A Multi-institutional Study. JAMA Surg. 2018;153(2):123-129. doi:10.1001/jamasurg.2017.3422

Metcalfe K, Eisen A, Senter L, et al. International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation. Br J Cancer. 2019;121(1):15-21. doi:10.1038/s41416-019-0446-1

Boissier S, Ferreras M, Peyruchaud O, et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. 2000;60(11):2949-2954

Chlebowski RT, Chen Z, Cauley JA, et al. Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol. 2010;28(22):3582-3590. doi:10.1200/JCO.2010.28.2095

Daubiné F, Le Gall C, Gasser J, Green J, Clézardin P. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst. 2007;99(4):322-330. doi:10.1093/jnci/djk054

van der Pluijm G, Vloedgraven H, van Beek E, van der Wee-Pals L, Löwik C, Papapoulos S. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest. 1996;98(3):698-705. doi:10.1172/JCI118841

Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials [published correction appears in Lancet. 2016 Jan 2;387(10013):30] [published correction appears in Lancet. 2017 Jun 24;389(10088):2472]. Lancet. 2015;386(10001):1353-1361. doi:10.1016/S0140-6736(15)60908-4

Dhesy-Thind S, Fletcher GG, Blanchette PS, et al. Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017;35(18):2062-2081. doi:10.1200/JCO.2016.70.7257

Gnant M, Harbeck N, Thomssen C: St. Gallen/Vienna 2017: A Brief Summary of the Consensus Discussion about Escalation and De-Escalation of Primary Breast Cancer Treatment. Breast Care 2017;12:101-106. doi: 10.1159/000475698

Chlebowski RT, Chen Z, Cauley JA, et al. Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol. 2010;28(22):3582-3590. doi:10.1200/JCO.2010.28.2095

Vestergaard P, Fischer L, Mele M, Mosekilde L, Christiansen P. Use of bisphosphonates and risk of breast cancer. Calcif Tissue Int. 2011;88(4):255-262. doi:10.1007/s00223-011-9463-7

Narodowa Biblioteka Medyczna Stanów Zjednoczonych. ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT02781805 (2016). Dostęp 16.01.2023.

Narodowa Biblioteka Medyczna Stanów Zjednoczonych. ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT03323658 (2017). Dostęp 16.01.2023.

Rejestr badań klinicznychUE. ClinicalTrialsRegister.eu, https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010260-41 (2009). Dostęp 16.01.2023.

Moon RC, Thompson HJ, Becci PJ, et al. N-(4-Hydroxyphenyl)retinamide, a new retinoid for prevention of breast cancer in the rat. Cancer Res. 1979;39(4):1339-1346.